CalmiGo

Company Overview

Snapshot

Founded in March 2021 by Adi Wallach, Iko Hason, and Orna Levin M.D., CalmiGo operates with 11–50 employees. The company has raised $6 million across 3 funding rounds from 6 investors.

Business overview

CalmiGo develops a drug-free device designed to provide immediate relief from anxiety and distress by regulating breathing patterns and senses. The core technology utilizes personalized breathing regulation, multisensory stimulation, and soothing scents to decrease stress hormone levels, activating the calming parasympathetic nervous system. CalmiGo serves patients in the healthcare sector, operating within the Health Tech & Life Sciences industry, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In September 2025, CalmiGo announced the addition of Eyal Waldman and Dr. Martin Rosenzweig to its board of directors. This strategic move signals a strengthening of the company's leadership and expertise, potentially paving the way for accelerated growth and market penetration in the health tech and medical device sectors. For investors, this indicates a commitment to robust governance and strategic guidance, enhancing the company's long-term viability and appeal.

Company Intelligence Q&A

What is CalmiGo's primary product?

CalmiGo's primary product is a drug-free device that provides immediate relief from anxiety, stress, and panic attacks by regulating breathing patterns and senses through personalized breathing regulation, multisensory stimulation, and soothing scents.

When was CalmiGo founded and by whom?

CalmiGo was founded in March 2021 by Adi Wallach, Iko Hason, and Orna Levin M.D.

What was a key strategic development for CalmiGo in September 2025?

In September 2025, CalmiGo announced the appointment of Eyal Waldman and Dr. Martin Rosenzweig to its board of directors, strengthening its leadership team.

What was a significant distribution milestone for CalmiGo in September 2021?

In September 2021, CalmiGo became available at select CVS Health stores nationwide, expanding its market reach for its anxiety relief device.